X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs ORCHID PHARMA LTD - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA ORCHID PHARMA LTD TORRENT PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x 44.2 0.1 29,647.1% View Chart
P/BV x 6.2 0.2 3,537.5% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 TORRENT PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
ORCHID PHARMA LTD
Sep-13
TORRENT PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs1,550194 799.0%   
Low Rs1,14435 3,267.1%   
Sales per share (Unadj.) Rs354.7276.5 128.3%  
Earnings per share (Unadj.) Rs40.1-79.2 -50.6%  
Cash flow per share (Unadj.) Rs64.2-43.5 -147.8%  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs273.153.9 506.4%  
Shares outstanding (eoy) m169.2270.45 240.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.80.4 916.8%   
Avg P/E ratio x33.6-1.4 -2,324.8%  
P/CF ratio (eoy) x21.0-2.6 -795.8%  
Price / Book Value ratio x4.92.1 232.3%  
Dividend payout %34.90-   
Avg Mkt Cap Rs m227,8978,067 2,825.2%   
No. of employees `00014.72.8 525.0%   
Total wages/salary Rs m11,3532,527 449.2%   
Avg. sales/employee Rs Th4,083.06,956.1 58.7%   
Avg. wages/employee Rs Th772.3902.5 85.6%   
Avg. net profit/employee Rs Th461.3-1,993.0 -23.1%   
INCOME DATA
Net Sales Rs m60,02119,477 308.2%  
Other income Rs m2,988407 733.9%   
Total revenues Rs m63,00919,884 316.9%   
Gross profit Rs m13,4931,103 1,223.7%  
Depreciation Rs m4,0862,519 162.2%   
Interest Rs m3,0855,227 59.0%   
Profit before tax Rs m9,310-6,236 -149.3%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m2,529-125 -2,019.7%   
Profit after tax Rs m6,781-5,580 -121.5%  
Gross profit margin %22.55.7 397.1%  
Effective tax rate %27.22.0 1,352.9%   
Net profit margin %11.3-28.7 -39.4%  
BALANCE SHEET DATA
Current assets Rs m52,62311,014 477.8%   
Current liabilities Rs m52,02232,060 162.3%   
Net working cap to sales %1.0-108.1 -0.9%  
Current ratio x1.00.3 294.4%  
Inventory Days Days12095 126.0%  
Debtors Days Days7634 227.2%  
Net fixed assets Rs m85,01629,440 288.8%   
Share capital Rs m846705 120.1%   
"Free" reserves Rs m45,3762,043 2,221.5%   
Net worth Rs m46,2223,800 1,216.4%   
Long term debt Rs m41,1159,018 455.9%   
Total assets Rs m142,43246,510 306.2%  
Interest coverage x4.0-0.2 -2,080.6%   
Debt to equity ratio x0.92.4 37.5%  
Sales to assets ratio x0.40.4 100.6%   
Return on assets %6.9-0.8 -911.4%  
Return on equity %14.7-146.9 -10.0%  
Return on capital %14.2-3.7 -380.0%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m14,5807,513 194.1%   
Fx outflow Rs m3,6005,649 63.7%   
Net fx Rs m10,9801,865 588.9%   
CASH FLOW
From Operations Rs m8,9421,682 531.7%  
From Investments Rs m-47,070-9,860 477.4%  
From Financial Activity Rs m34,1746,644 514.4%  
Net Cashflow Rs m-3,655-1,535 238.1%  

Share Holding

Indian Promoters % 71.5 32.3 221.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 4.6 152.6%  
FIIs % 12.6 3.3 381.8%  
ADR/GDR % 0.0 4.6 -  
Free float % 8.8 55.3 15.9%  
Shareholders   26,511 84,811 31.3%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   GSK PHARMA  JUBILANT LIFE SCIENCES  BIOCON LTD  IPCA LABS  NATCO PHARMA  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Up Over 240 Points; Rupee Touches Record Low(12:30 pm)

After opening the day in the green, stock markets in India have continued their momentum and are presently trading on a positive note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7% (Quarterly Result Update)

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Should You Buy These Mouthwatering High Dividend Stocks?(Profit Hunter)

Aug 1, 2018

Many stocks are yielding dividends even upwards of 4%-5%. Here are the kinds you should pick, and the ones to avoid.

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

NFO - Axis Equity Hybrid Fund: A Worthy Proposition?(Outside View)

Aug 1, 2018

PersonalFN explains if NFO: Axis Equity Hybrid Fund, would be a worthy proposition currently.

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Aug 14, 2018 01:59 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS